To reinforce this concept, the utilization of the CXCR2 inhibitor SB265610 significantly mitigated the expedited tumor expansion and the accumulation of MDSCs, which were both induced by the knockdown of CUL4B. This evidence concerns the gene CUL4B and neoplasm.